A5090656958- Inflammatory Bowel Disease
- Microscopic Colitis
- Gut microbiota and health
- Neonatal Respiratory Health Research
- Infant Nutrition and Health
- Psoriasis: Treatment and Pathogenesis
- Eosinophilic Esophagitis
- Hidradenitis Suppurativa and Treatments
- Autoimmune and Inflammatory Disorders
- Dermatology and Skin Diseases
- Diabetes and associated disorders
IRCCS Humanitas Research Hospital
2024
Czech Academy of Sciences, Institute of Microbiology
2021-2023
Czech Academy of Sciences
2021-2023
Inflammatory bowel diseases (IBD) are chronic disorders of the gastrointestinal tract that have been linked to microbiome dysbiosis and immune system dysregulation. We investigated longitudinal effect anti-TNF therapy on gut microbiota composition specific response commensals in IBD patients. The study included 52 patients tracked over 38 weeks 37 healthy controls (HC). To characterize diversity microbiota, we used amplicon sequencing V3V4 region 16S rRNA for bacterial community ITS1 fungal...
Crohn's disease (CD) and ulcerative colitis (UC) are two forms of inflammatory bowel (IBD), where the role gut but not skin dysbiosis is well recognized. Inhibitors TNF have been successful in IBD treatment, up to a quarter patients suffer from unpredictable adverse events (SkAE). For this purpose, we analyzed temporal dynamics microbiota serum markers inflammation epithelial barrier integrity during anti-TNF therapy SkAE manifestation patients. We observed that signature differs markedly...
Tumor necrosis factor-alpha (TNF-α) agonists revolutionized therapeutic algorithms in inflammatory bowel disease (IBD) management. However, approximately every third IBD patient does not respond to this therapy the long term, which delays efficient control of intestinal inflammation. We analyzed power serum biomarkers predict failure anti-TNF-α. collected 38 patients at prescription and weeks later them with relation response (no-, partial-, full response). used enzyme-linked immunosorbent...
Background Ustekinumab, is a new therapy for patients with IBD, especially suffering from Crohn’s disease (CD) who did not respond to anti-TNF treatment. To shed light on the longitudinal effect of ustekinumab immune system, we investigated skin and gut microbiota composition, specific response commensals, various serum biomarkers. Methodology/Principal findings We recruited 11 IBD were monitored over 40 weeks 39 healthy controls (HC). found differences in concentrations levels...
Abstract Background Crohn’s disease (CD) and ulcerative colitis (UC) are two forms of inflammatory bowel (IBD), where gut but not skin dysbiosis is well recognized. Tumor-necrosis factor alpha (TNFα) blockers have been successful in IBD treatment, up to a quarter patients suffer from adverse events (SkAE), for which we do tool predict them. Therefore, examined the microbiota composition at several body sites by 16S bacterial profiling. Moreover, quantified 22 serum markers inflammation...